Ambisome (liposomal amphotericin B): A comparative review

Journal of Clinical Pharmacology

Volumn 38, Issue 7, 1998, Pages 583-592

  Boswell, G W ^a   Buell, D ^a   Bekersky, I ^a  

^a ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ERGOSTEROL;

ASPERGILLOSIS; CANDIDIASIS; CELL MEMBRANE; CELL WALL; CHILL; CRYPTOCOCCOSIS; CYTOLYSIS; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG LABELING; DRUG RELEASE; DRUG STRUCTURE; FEVER; HUMAN; MYCOSIS; PARTICLE SIZE; REVIEW; RIGOR;

EID: 0031904301     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04464.x     Document Type: Review

References (30)

1. Fujii G: Liposomal amphotericin B (AmBisome): realization of the drug delivery concept. Surfactant Sci Ser 1996;62:491-526.
2. Hiemenz JW, Walsh TJ: Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996; 22(Suppl 2):S133-S144.
3. Adler-Moore J, Proffitt RJ: Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J Liposome Res 1993;3:429-450.
4. Perkins WR, Minchey SR, Boni LT, Swenson CE, Popescu MC, Paternack RF, Janoff AS: Amphotericin B phospholipid interactions responsible for reduced mammalian cell toxicities. Biochem Biophys Acta 1992;1107:271-282.
5. Fielding RM, Singer AW, Wang LH, et al: Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob Agents Chemother 1992;36:299-307.
6. Walsh TJ, Yeldandi V, McEvory M, Gonzales C, Chanok S, Friefeld A, et al: Safety, tolerance and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother (in press).
7. Sequus Pharmaceuticals, Inc: Amphotericin B cholesteryl sulfate complex for injection. In, Physicians Desk Reference. Fiftysecond edition. Montvale, NJ: Medical Economics Data, 1998; 2764-2768.
8. The Liposome Company, Inc: Abelcet, amphotericin B lipid complex injection. In, Physicians Desk Reference. Fifty-second edition. Montvale, NJ: Medical Economics Data, 1988;1516-1518.
9. Janoff AS, Boni LT, Popescu MC, Minchey SR, Cullis PR, Madden TD, et al: Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci U S A 1988;85: 6122-6126.
10. Guo LSS, Working PK: Complexes of amphotericin B and cholesteryl sulfate. J Liposome Res 1993;3:473-490.
11. Butler WT, Cotlove E: Increased permeability of human erythrocytes induced by amphotericin B. J Infect Dis 1971;123:341-350.
12. Adler-Moore J: AmBisome targeting to fungal infections. Bone Marrow Transplant 1994;14(Suppl 5):S3-S7.
13. NeXstar Pharmaceuticals, Inc.: AmBisome Product Monograph: Mechanism of Action. San Dimas, CA: NeXstar Pharmaceuticals, Inc., 1996.
14. Physicians Desk Reference. Fiftieth edition. Montvale, NJ: Medical Economics Data, 1996.
15. Fromtling RA: Experimental and clinical pharmacokinetics of amphotericin B lipid complex. Drugs Today 1996;32:403-409.
16. Dayan AD, Working PK: Non-clinical studies of the efficacy, pharmacokinetics and safety of amphotericin B colloidal dispersion. Round Table Series 1993;32:12-26.
17. Sharkey PK, Graybill SR, Johnson ES, Hausrath G, Pollard RB, Kolokathis A, et al: Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22:315-321.
18. Anaissie EJ, White M, Uzun C, Singer C, Bodey GP, Azarnia N, et al: Amphotericin B lipid complex versus amphotericin B for treatment of hematogenous and invasive candidiasis: a prospective randomized multicenter trial. In, Proceedings of the Thirty-Fifth ICAAC. Washington, DC: American Society for Microbiology, 1995;21:30.
19. Clark A, Chopra R, McKendrick S, Tansey P, Franklin IM: Comparative analysis of liposomal and lipid complex amphotericin B preparations (ASH abstract 2426). Blood 1997;90(Suppl 1):544a.
20. Boswell G, Bekersky I, Buell D, Hiles R, Walsh TJ: Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B (AmBisome) in rats. Antimicrob Agents Chemother 1998;42:263-368.
21. Fielding RM, Smith PC, Wang LH, Porter J, Guo LSS: Comparative pharmacokinetics of amphotericin B after a administration of novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother 1991;35:1208-1213.
22. van Etten EWM, van der Heuvel-de Groot C, Bakker-Woudenberg IAJM: Efficacies of amphotericin B-deoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidiasis in immunocompetent and leukopenic mice. J Antimicrob Chemother 1993;32:723-739.
23. Lee JW, Amantea MA, Francis PA, Navarro EE, Bacher J, Pizzo PA, et al: Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother 1994;38:713-718.
24. Garcia A, Adler-Moore J, McAndrews B: Prophylactic Treatment of Murine Candidiasis with Single High Dose AmBisome. NeXstar Report 232-93108. San Dimas, CA: NeXstar Pharmaceuticals, Inc., 1996.
25. Bekersky I: The toxicokinetics of amphotericin B in dogs during a 30-day intravenous toxicity study of AmBiosome (liposomal amphoteracin B). Report R95-0161-AMP-P2-E. Deerfield, IL: Fujisawa USA, 1996. review).
26. Fielding RM, Singer AW, Wang LH, Babbar S, Guo LSS: Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob Agents Chemother 1992;36:299-307.
27. Bhamra R, Sa'ad A, Bolcsak L, Swenson C, Janoff A: Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats. Antimicrob Agents Chemother 1997;41:886-892.
28. Adler-Moore J, Coulter DM, Proffitt RT: Interaction of Fungizone and AmBisome with Whole Blood and Isolated Human Red Blood Cells. Report 232-93099. San Dimas, CA: NeXstar Pharmaceuticals.
29. Buell D, Rivera M, Gordon J, Kline S, Thuma N: AmBisome rescue in patients who have received other lipid formulations of amphotericin B (abstract 026). In, Proceedings of the Eighth Focus on Fungal Infections, March 4-6, 1998, Orlando, FL.
30. Olsen SJ, Swerdel MR, Blue B, Clark JM, Bonner DP: Tissue distribution of amphotericin B lipid complex in laboratory animals. J Pharm Pharmacol 1991;43:831-835.